Nelarabine
From Wikipedia, the free encyclopedia
 |
|
|
Nelarabine
|
|
| Systematic (IUPAC) name | |
| (2R,3S,4R,5R)-2-(2-amino-6-methoxy-purin-9-yl)- 5-(hydroxymethyl)oxolane-3,4-diol |
|
| Identifiers | |
| CAS number | |
| ATC code | L01 |
| PubChem | |
| Chemical data | |
| Formula | C11H15N5O5 |
| Mol. mass | 297.268 g/mol |
| Pharmacokinetic data | |
| Bioavailability | n/a |
| Protein binding | <25% |
| Metabolism | By adenosine deaminase, to 9-β-D-arabinofuranosylguanine |
| Half life | 30 minutes (nelarabine) 3 hours (ara-G) |
| Excretion | Renal |
| Therapeutic considerations | |
| Pregnancy cat. |
D(US) |
| Legal status | |
| Routes | Intravenous |
Nelarabine is a chemotherapy drug used in T-cell acute lymphoblastic leukemia. It was previously known as 506U78.
Nelarabine is a purine nucleoside analog converted to its corresponding arabinosylguanine nucleotide triphosphate (araGTP), resulting in inhibition of DNA synthesis and cytotoxicity. Pre-clinical studies suggest that T-cells are particularly sensitive to nelarabine. In October 2005, it was approved by the FDA for T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma that has not responded to or has relapsed following treatment with at least two chemotherapy regimens. Complete responses have been achieved with this medication.
It is marketed as Arranon by GlaxoSmithKline.
